INSERM chair: studies on the development of certain tumour pathologies

Dr Aurélien Serandour arrived at Centrale Nantes as part of an Inserm chair under the supervision of Dr Stéphane Minvielle (Nantes-Angers Cancer and Immunology Research Centre - CRCINA). The team is studying mutations in the cell genome in cases of multiple myeloma, a form of cancer that affects the bone marrow and for which the risk of relapse in treated patients is significant. To this end, it relies on data collected at the Nantes University Hospital Center in Professor Philippe Moreau's (a specialist in multiple myeloma) department.

on February 1, 2018

For several years, Nantes-based researchers have specialized in the study and understanding of the development of certain tumor pathologies in humans and, in particular, multiple myeloma, working with Pr Philippe Moreau's Hematology Department at Nantes University Hospital.

In this respect, a CRCINA team developed "an innovative approach at the crossroads of genetics, that is to say the study of DNA, and epigenetics" in order to understand the progression of the disease and the mechanisms by which certain tumour cells avoid treatment, causing relapses, explained Stéphane Minvielle, CNRS senior research associate and group leader at CRCINA. 

Based on data collection and analysis, the Nantes researchers wanted to go further by integrating other disciplinary fields into their approach, such as bioinformatics and biostatistics in order to develop cell modeling.

As part of a research programme funded by an Inserm chair, this new approach aimed to allow researchers to identify the genes and cell clones responsible for multiple myeloma (biomarkers) and better understand the mechanisms by which the disease develops. "By analyzing the data, we will first be able to see which cells are involved in the initiation and progression of the pathology and then define a cancer identity card for more personalized treatment" explained Aurélien Serandour, associate professor at Centrale Nantes and holder of the Inserm Chair.

This new interdisciplinary approach could ultimately be applied to other pathologies than multiple myeloma.
Published on January 23, 2020 Updated on November 23, 2020